“Some 16 million American women are impacted by sexual dysfunction,” according to Irwin Goldstein, the secretary of the International Society for the Study of Women's Sexual Health, and a medical advisor for EmpowHER. His statement appeared in a PR Newswire news release.
The news release also noted that according to the Journal of the American Medical Association, 43 percent of women have sexual dysfunctions, compared with 31 percent of men. One in 10 women has experienced hypoactive sexual desire disorder (HSDD). HSDD is an absence of sexual desire and fantasies, that causes distress and does not have an obvious cause.
Even with these high numbers, the U.S. Food and Drug Administration (FDA) has yet to approve a single drug to treat female sexual dysfunction. For men, it’s a different story. There are 26 approved drugs to treat male sexual dysfunction.
This disparity has become a rallying point for advocates who suggest that the FDA seems more eager to approve sex-enhancing drugs for men than for women.
A diverse group of women's health and research organizations launched "Even the Score." This advocacy campaign was created to serve as a voice for American women who believe that it's time for the FDA to level the playing field when it comes to the treatment of HSDD.
EmpowHER is a founding supporter of Even the Score. EmpowHER's founder and chairman Michelle King Robson said, “this is about more than just ‘lifestyle’ drugs; this is life altering. Women’s lives are being affected by this condition every single day.”
Serra Sippel, president of the Center for Health and Gender Equity wrote in Huffington Post that when a woman or man suffers from a form of sexual dysfunction, their ability to have a satisfying sex life is curtailed and personal relations with a partner or spouse also can be damaged.